New Space News: Innovative drug concept stocks staged a short-term rally, with CSOP Hang Seng Biotech ETF (03174.HK) surging over 2.4% intraday.

NewTimeSpace News: On March 27, innovative drug concept stocks staged a short-term rally, with Lianhuan Pharma hitting the daily limit-up, while Jiuzhitang, Guangyuanyuan, Hotgen, Enores, and Wonder Pharma followed suit. CSOP Hang Seng Biotech (03174.HK) opened up over 2.4%.

According to statistics, domestic innovative drug companies concluded 30 BD transactions in January this year, comprising 20 licensing deals with overseas pharmaceutical firms and 10 cooperation agreements between local players. Notably, January saw 8 blockbuster overseas licensing transactions each exceeding USD 1 billion in total value, with the highest single transaction reaching USD 18.5 billion—a record-breaking figure for domestic pharmaceutical out-licensing.

CSOP Hang Seng Biotech (03174.HK), issued by CSOP Asset Management and listed on the Hong Kong Stock Exchange, tracks the Hang Seng Biotech Index. This ETF focuses on biotech leaders listed in Hong Kong, characterized by high volatility and elasticity, suitable for investors bullish on innovative drugs, CXO, vaccines, and gene therapy sectors.

On the news front, Hengrui Medicine released its 2025 annual report on the evening of March 25. The company achieved record-high revenue and net profit during the reporting period, with total operating income reaching RMB 31.629 billion, up 13.02% year-on-year, and net profit attributable to shareholders of RMB 7.711 billion, up 21.69% year-on-year. Innovative drug sales revenue amounted to RMB 16.342 billion, up 26.09% year-on-year, accounting for 58.34% of total drug sales revenue; out-licensing revenue reached RMB 3.392 billion, up 25.62% year-on-year.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.